Current Report Filing (8-k)
September 21 2021 - 3:06PM
Edgar (US Regulatory)
0001599298
false
0001599298
2021-09-21
2021-09-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September
21, 2021
Summit Therapeutics Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
Delaware
|
001-36866
|
37-1979717
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
One Broadway, 14th Floor,
Cambridge,
MA
|
02142
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code: 617-514-7149
Not Applicable
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common stock, $0.01 par value per share
|
SMMT
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Summit Therapeutics
Inc. (“Summit”) received feedback from the United States Food and Drug Administration (the “FDA”) that the FDA
does not agree with the change to the primary endpoint that Summit proposed and has subsequently implemented in its ongoing Phase III
Ri-CoDIFy studies when combining the studies. As Summit previously communicated, it has combined the Phase III studies into a single
study and will provide the combined results to all stakeholders, as the top line results become available. These top line
results will best inform all parties as to the next appropriate course of action regarding ridinilazole. Summit
anticipates communicating these results during the first quarter of 2022.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
SUMMIT THERAPEUTICS INC.
|
|
|
|
|
Date: September 21, 2021
|
By:
|
/s/ Elaine Stracker
|
|
|
Elaine Stracker
|
|
|
General Counsel
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024